Key Points Bitcoin’s price went nowhere in 2025. It could bounce back in 2026 as institutional investors ramp up their purchases. Favorable macro tailwinds could also drive its price higher. 10 stocks we like better than Bitcoin › 2025 was a disappointing year for Bitcoin (CRYPTO: BTC) bulls. The world's top cryptocurrency saw wild swings, but it ultimately fell more than 5% for the whole year. Th...
Key Points Bitcoin’s price went nowhere in 2025. It could bounce back in 2026 as institutional investors ramp up their purchases. Favorable macro tailwinds could also drive its price higher. 10 stocks we like better than Bitcoin › 2025 was a disappointing year for Bitcoin (CRYPTO: BTC) bulls. The world's top cryptocurrency saw wild swings, but it ultimately fell more than 5% for the whole year. That drop can be attributed to Treasury yields, which remained high even as the Fed cut its benchmark rate, to messy macro headwinds, and to a rotation toward more conservative investments. Bitcoin is off to a better start in 2026. It's only risen about 1% year-to-date as of this writing, but a few catalysts might stabilize its price and drive it higher throughout the rest of the year. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks » What are Bitcoin's catalysts for 2026? It might initially seem like Bitcoin's most significant catalysts are in the rearview mirror. In 2024, the Securities and Exchange Commission (SEC) approved its first spot price exchange-traded funds (ETFs), and the halving (which halves mining rewards every 4 years) occurred. The Fed also halted its rate hikes, which had driven investors away from Bitcoin and other speculative cryptocurrencies, and reduced those rates six times throughout 2024 and 2025. With a lot of those catalysts already priced in, Bitcoin no longer seemed like a compelling investment for growth-oriented investors. However, Bitcoin's stabilization could drive its evolution into a safe haven play like gold and silver this year. Bitcoin is often called "digital gold" because it is mined with powerful custom chips using the energy-intensive proof-of-work (PoW) mechanism. Nearly 20 million of its 21 million tokens have already been mined, and its scheduled four-year halvings make it increasingly difficult to mine the token...
The stock market has been kind to growth investors for about two years now. It's a welcome change of pace from the inflation crisis in 2022. The tech-heavy Nasdaq Composite (NASDAQINDEX: ^IXIC) index is up by 67% in 24 months, or 70% in terms of dividend-boosted total returns. There's a downside to a surging bull market, though. There are fewer slam-dunk buys available these days, as many of yeste...
The stock market has been kind to growth investors for about two years now. It's a welcome change of pace from the inflation crisis in 2022. The tech-heavy Nasdaq Composite (NASDAQINDEX: ^IXIC) index is up by 67% in 24 months, or 70% in terms of dividend-boosted total returns. There's a downside to a surging bull market, though. There are fewer slam-dunk buys available these days, as many of yesteryear's bargains are soaring again. But "fewer" doesn't mean "zero." If you have $1,000 of investable funds on hand (or any other amount, really), I highly recommend grabbing a few shares of Fiverr International (NYSE: FVRR). This high-octane growth stock never got the memo about a broad market rebound, and the stock is down 18% in two years instead. That makes Fiverr a no-brainer buy today. Let me show you why. Rumors of Fiverr's death have been greatly exaggerated Many investors expected Fiverr to shrivel up and fade away after the coronavirus pandemic. The company helps freelancers connect with clients and the other way around. That idea was hot amid the lockdowns of 2020, and then people got back to regular nine-to-five work again. That's the theory behind Fiverr's slumping stock chart, anyway. Fiverr's time in the limelight was surely over as soon as the first COVID-19 vaccines were widely available. Fiverr's gig economy growth But the company never stopped growing. As it turns out, plenty of the people who got their first taste of the gig economy four years ago liked what they saw. Fiverr's trailing twelve-month sales have increased by 36% in three years while free cash flows nearly tripled: Sure, there was a slowdown in the inflation crisis. Equipped with a robust balance sheet and solid cash profits, Fiverr survived that challenge and thrived on the other side. Yet, market makers continued to assume the worst and drove the stock price 86% lower over the same period. I don't know about you, but I don't think that these conflicting chart lines belong in the same graph...
Earnings Call Insights: Microsoft Corporation (MSFT) Q2 2026 Management View CEO Satya Nadella highlighted that "the Microsoft Cloud surpassed $50 billion in revenue for the first time, up 26% year-over-year, reflecting the strength of our platform and accelerating demand." Nadella described the company as being in "the beginning phases of AI diffusion and its broad GDP impact," with a rapidly exp...
Earnings Call Insights: Microsoft Corporation (MSFT) Q2 2026 Management View CEO Satya Nadella highlighted that "the Microsoft Cloud surpassed $50 billion in revenue for the first time, up 26% year-over-year, reflecting the strength of our platform and accelerating demand." Nadella described the company as being in "the beginning phases of AI diffusion and its broad GDP impact," with a rapidly expanding total addressable market across the technology stack. Nadella detailed major infrastructure developments, including "a 50% increase in throughput... in one of our highest volume workloads, OpenAI inferencing, powering our Copilots," and the launch of the Maia 200 accelerator, which "delivers 10-plus petaFLOPS at FP4 precision with over 30% improved TCO compared to the latest generation hardware in our fleet." The company added "nearly 1 gigawatt of total capacity this quarter alone." Microsoft expanded its AI model ecosystem, adding "support for GPT-5.2 as well as Claude 4.5," and noted over 1,500 customers using both Anthropic and OpenAI models on Foundry. Fabric's revenue run rate is "now over $2 billion with over 31,000 customers," up 60% year-over-year. Foundry customers spending $1 million plus per quarter grew nearly 80%, and over 250 customers are on track to process over 1 trillion tokens this year. Copilot momentum was emphasized: "Daily users of our Copilot app increased nearly 3x year-over-year." Microsoft 365 Copilot seat adds were up over 160% year-over-year, reaching 15 million paid seats, and the number of customers with over 35,000 seats tripled year-over-year. CFO Amy Hood stated, "With growing demand for our offerings and focused execution by our sales teams, we again exceeded expectations across revenue, operating income and earnings per share, while investing to fuel long-term growth." Hood added, "This quarter, revenue was $81.3 billion, up 17%... Earnings per share was $4.14, an increase of 24%." Outlook Microsoft expects Q3 total company revenu...
Steven Choi, General Manager of Tencent Cloud Hong Kong & Macau , said, "We are excited to support Bupa in delivering seamless and smarter healthcare experiences to its customers. By leveraging Tencent's advanced PalmAI technology—which integrates dual biometric identification using both palm print and palm vein patterns—we are enabling a secure, contactless, and truly frictionless check-in experi...
Steven Choi, General Manager of Tencent Cloud Hong Kong & Macau , said, "We are excited to support Bupa in delivering seamless and smarter healthcare experiences to its customers. By leveraging Tencent's advanced PalmAI technology—which integrates dual biometric identification using both palm print and palm vein patterns—we are enabling a secure, contactless, and truly frictionless check-in experience. Compared with traditional methods such as facial or fingerprint recognition, this solution enhances security and accuracy, reduces waiting times, and offers a more hygienic, mask-friendly experience for users." Since its launch in 2022, Tencent PalmAI has been adopted by tens of millions of users globally, supporting diverse use cases from access control and identity verification to payments—enhancing user experience while improving operational efficiency. Bupa's recent adoption of PalmAI was implemented by Tencent Cloud, the cloud business of Tencent. Powered by Tencent PalmAI, the service uses AI-driven biometric technology that captures both palm print and real-life palm vein patterns to deliver secure, reliable, and hygienic authentication. With dual biometric identification, customers can simply place their palm over a high-precision scanner at the check-in kiosk for instant, document-free verification—without the need to remove masks or have physical contact with staff. For added flexibility, customers can also choose to check in using a QR code, ensuring a smooth and convenient experience for everyone. This innovation not only improves speed and convenience but also strengthens privacy and hygiene, supporting a smarter, more personalised healthcare journey. The Express Check-in, a first-of-its-kind contactless check-in experience in Hong Kong's private healthcare sector officially launched today across 20 designated Bupa's network clinics citywide, offering customers a faster and more convenient way to access care. Among these locations, the flagship medical ce...
發展局匯報北都進展 議員質疑屢斬件式申撥款 甯漢豪：免粗略估算遭「講故事」 To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video 【有線新聞】立法會發展事務委員會，發展局匯報北部都會區規劃進展，有議員提出政府常以「斬件式」申請撥款，...
發展局匯報北都進展 議員質疑屢斬件式申撥款 甯漢豪：免粗略估算遭「講故事」 To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video 【有線新聞】立法會發展事務委員會，發展局匯報北部都會區規劃進展，有議員提出政府常以「斬件式」申請撥款，希望政府交代大概發展預算，發展局局長甯漢豪解釋難以做估算，亦不希望社會對粗略的估算「講故事」引起誤會。 新界西北（實政圓桌）莊豪鋒：「現在北都發展經常性地『斬件式』來立法會申請撥款，就算是同一個產業區都分幾次，例如研究設計一筆，土地平整又申請一筆，建橋建路又是一筆。 發展局局長甯漢豪：「我們很難一概而論有一個總額，而客觀環境我們也很擔心，我們粗略地給出一個總額後，大家即使議員明白，但社會很多時會拿著這個總額說很多故事，說我們庫房『乾塘』，還要投資這麼多，引起很多誤會。」
Key Points Recursion Pharmaceuticals lagged the market last year. The stock doesn't have significant catalysts on the horizon. The biotech's long-term prospects also look uncertain. 10 stocks we like better than Recursion Pharmaceuticals › Recursion Pharmaceuticals (NASDAQ: RXRX) is a small-cap biotech with a mission. The company is looking to revolutionize the way we develop drugs through the use...
Key Points Recursion Pharmaceuticals lagged the market last year. The stock doesn't have significant catalysts on the horizon. The biotech's long-term prospects also look uncertain. 10 stocks we like better than Recursion Pharmaceuticals › Recursion Pharmaceuticals (NASDAQ: RXRX) is a small-cap biotech with a mission. The company is looking to revolutionize the way we develop drugs through the use of artificial intelligence (AI). However, the company has had little success so far. Last year, Recursion Pharmaceuticals' shares fell significantly. Could the company bounce back this year? Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » There could be some clinical progress Recursion Pharmaceuticals uses an AI-powered operating system to test clinical compounds. The most promising get sent to clinical trials. The typical success rate for new compounds entering the clinic isn't high. Most never make it to the market. Recursion argues that its approach could boost the probability of success while also cutting the time and money typically spent on preclinical studies. If the biotech is right, it could transform the pharmaceutical industry. But do we have good reasons to believe Recursion will achieve its goals? Not so much. Recursion Pharmaceuticals' most advanced candidates are currently in mid-stage studies. We could see several data readouts through the next year or so. For instance, Recursion Pharmaceuticals expects results from a clinical trial for REC-1245, a potential cancer medicine, during the first half of the year. It could also see a data readout from a study of REC-102 -- a potential medicine for a disease called hypophosphatasia (which weakens patients' bones and teeth) -- during the second half of the year. It's important to note, though, that these will be phase 1 data readouts. These are unlikely to move the stock significantly, since early-stage studies tend to focus on ...